Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa

Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.

Study Overview

• Status: Withdrawn
• Conditions: Classic Kaposi Sarcoma; AIDS-related Kaposi Sarcoma
• Intervention / Treatment: Procedure: laboratory biomarker analysis; Drug: sunitinib malate; Procedure: pharmacological study

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the clinical response of sunitinib malate in patients with Kaposi sarcoma (KS) in Uganda and Kenya.

II. Compare clinical response rates in endemic versus epidemic (AIDS) KS. III. Determine the safety and tolerability of sunitinib malate in patients with endemic or epidemic (AIDS) KS.

SECONDARY OBJECTIVES:

I Monitor the impact of sunitinib malate on underlying HIV-1 and Kaposi sarcoma-associated herpesvirus (KSHV) viral infection (HIV-1 plasma RNA and KSHV cell-associated DNA).

II. Evaluate morphological changes in KS lesions after treatment. III. Determine the pharmacokinetic profile of sunitinib malate in patients with KS.

IV Evaluate KSHV gene expression in endemic and epidemic KS lesions in patients in Uganda and Kenya.

OUTLINE: This is a multicenter study. Patients are stratified according to HIV-serostatus (endemic [HIV-seronegative] vs epidemic [HIV-seropositive/AIDS] kaposi sarcoma).

Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.

Patients undergo tumor tissue and blood sample collection periodically for correlative and pharmacokinetic studies. Samples are analyzed for CD4 lymphocyte counts, HIV-1 plasma RNA levels, KSHV specific antibodies, expression pattern of KSHV in vitro and in vivo, expression of latently versus lytically expressed genes in tumor tissue, and plasma concentrations of sunitinib malate and its active metabolite, SU12662.

After completion of study treatment, patients are followed every 6 weeks.

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• ECOG performance status 0-1
• Documented HIV-serostatus [HIV-seronegative (endemic KS) or HIV-seropositive (epidemic/AIDS KS)]
• No symptomatic organ involvement, visceral crisis, or life-threatening disease (e.g., extensive or symptomatic pulmonary disease or reticuloendothelial system/hepatic involvement) for which aggressive double- or triple-drug combination chemotherapy for urgent cytoreduction is indicated (i.e., doxorubicin hydrochloride, bleomycin, and vinblastine [ABV], BV, or AV)
• Histologically confirmed Kaposi sarcoma
• Platelet count > 75,000/uL
• Life expectancy >= 24 weeks
• Absolute granulocyte count > 1,000/uL
• Hemoglobin > 8.0 g/dL OR hematocrit > 24%
• Serum creatinine =< 2.0 mg/dL
• AST < 3 times normal
• Fertile patients must use effective contraception
• Normal clinical cardiac examination and normotensive (systolic and diastolic BP < 140/90 mm Hg) documented on at least two occasions prior to enrollment
• Normal ECG including QTc interval < 500 msec
• Normal echocardiogram prior to enrollment (if feasibly possible)
• Must be able to swallow study medication
• No acute infections [Patients with chronic infections (e.g., malaria, tuberculosis, parasitic infections, or hepatitis B or C) that may be active but under treatment are allowed provided all eligibility criteria are met]
• At least 60 days since prior local treatment modalities (e.g., resection, cryosurgery, radiotherapy, or intralesional therapy) AND treated lesions must have clearly progressed following such therapies if the lesions are to be used as an index lesion
• No prior systemic anticancer therapy for Kaposi sarcoma
• Concurrent antiretroviral therapy required for HIV-seropositive patients (Patient must be on a stable regimen 8 weeks prior to study enrollment--An exception may be made for patients who have exhausted or are intolerant to all available regimens)
• No other concurrent systemic anticancer therapy
• Patient resides in Uganda or Kenya, East Africa

Exclusion Criteria:

• Pregnant or nursing
• Baseline diarrhea >= grade 2 by CTCAE

• Uncontrolled intercurrent illness including, but not limited to, any of the following:

  • Ongoing or acute active infection
  • Symptomatic congestive heart failure (NYHA class III or IV heart disease)
  • Unstable angina pectoris
• Uncontrolled intercurrent illness including, but not limited to, any of the following: 1) Cardiac arrhythmia (i.e., history of serious ventricular arrhythmia, ventricular fibrillation, or ventricular tachycardia >= 3 beats in a row OR QTc >= 500 msec) 2) Psychiatric illness or social situation that would limit compliance with study requirements

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Arm I; Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.	Procedure: laboratory biomarker analysis; Correlative study; Drug: sunitinib malate; Given orally; Other Names: Sutent; SU11248; sunitinib; Procedure: pharmacological study; Correlative study; Other Names: pharmacological studies

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response rate	The true response rate will be estimated based on the number of responses using a binomial distribution. The confidence intervals for them can be estimated using same distribution. Chi-square test or Fisher's exact test will be used to examine the difference of response rate between the two cohorts and log-rank test for the difference of survival outcomes.	Up to 11 months
Overall survival	Will be estimated by Kaplan-Meier method.	From the date of treatment to date of death, assessed up to 11 months
Progression-free survival	Will be estimated by Kaplan-Meier method.	From the date of treatment to date of death or date of disease progression, assessed up to 11 months
Levels of plasma-associated HIV-1 RNA viral load and cell-associated KSHV DNA viral load	Multivariate analysis will be performed using the Cox proportional hazards model. The effects of CD4+ lymphocyte counts, plasma HIV-1 RNA viral load and KSHV DNA level on the objective response rate will be evaluated using multivariate logistic regression.	Up to 11 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in CD4+ and CD8+ cell counts, levels of plasma-associated HIV-1 RNA, and cell-associated KSHV DNA load	For each treatment cohort and for all groups combined, the Wilcoxon signed rank test (the non-parametric version of paired T-test) will be used to evaluate the changes.	Baseline and 6 weeks

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
• Investigators: Principal Investigator: Scot Remick, Case Comprehensive Cancer Center

Study record dates

Study Major Dates

• Study Start: January 1, 2009
• Primary Completion (ACTUAL): October 1, 2010

Study Registration Dates

• First Submitted: August 24, 2007
• First Submitted That Met QC Criteria: August 24, 2007
• First Posted (ESTIMATE): August 27, 2007

Study Record Updates

• Last Update Posted (ESTIMATE): May 5, 2014
• Last Update Submitted That Met QC Criteria: May 2, 2014
• Last Verified: December 1, 2012

More Information

Terms related to this study

• Keywords: Treatment Experienced
• Additional Relevant MeSH Terms: Virus Diseases; Infections; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; DNA Virus Infections; Herpesviridae Infections; Neoplasms, Vascular Tissue; Sarcoma; Sarcoma, Kaposi; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Protein Kinase Inhibitors; Sunitinib
• Other Study ID Numbers: NCI-2009-00229 (REGISTRY: CTRP (Clinical Trial Reporting Program)); U01CA062502 (U.S. NIH Grant/Contract); CASE 1706 - AMC 049; CDR0000561751; CASE 1706 / AMC 049 (OTHER: Case Comprehensive Cancer Center); 7831 (OTHER: CTEP); P30AI036219 (NIH)